Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.56 |
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 4/20 | 0.51 |
| ▸ | CSF1R | P07333 | 4/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 3/20 | 0.49 |
| ▸ | BCR | P11274 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | DDX3X | O00571 | 1/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16592819 | 0.92 | EGFR (0.55) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL15859867 | 0.92 | EGFR (0.55) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL15860013 | 0.91 | EGFR (0.50) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL3808468 | 0.89 | ABL1 (0.58) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL15372886 | 0.88 | F10 (0.53) | ABL1SRCEGFRDDR2KIT | |
| SCHEMBL15859973 | 0.87 | BRAF (0.59) | ABL1EGFRKITBCRBRAF | |
| SCHEMBL15860120 | 0.86 | ABL1 (0.50) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL15860131 | 0.86 | EGFR (0.51) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL15860049 | 0.85 | ABL1 (0.49) | ABL1SRCEGFRLCKCSF1R | |
| SCHEMBL17313584 | 0.85 | ABL1 (0.49) | ABL1SRCEGFRLCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-20140170148-A1 | BISPECIFIC ANTIBODIES AGAINST HER2 | GENMAB A/S (DK) | 2014-06-19 | — | — | US | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170148-A1 | BISPECIFIC ANTIBODIES AGAINST HER2 | ERBB2, EGFR, ERBB3 | ABL1 56/4885SRC 231/4885EGFR 2/4885 |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ABL1, ABL2, SRC | ABL1 1/4885SRC 3/4885EGFR 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.